MiNK Therapeutics Inc (INKT) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... [Yahoo! Finance]
MiNK Therapeutics, Inc. (INKT)
Company Research
Source: Yahoo! Finance
Net Loss: $1.8 million or 5 per share for the three months; $8.3 million or 22 per share for the nine months ended September 30, 2024. Net Loss Comparison: $5.1 million or 15 per share for the three months; $17 million or 50 per share for the nine months ended September 30, 2023. Operating Burn Reduction: Nearly 60% reduction from the same time last year. Warning! GuruFocus has detected 2 Warning Signs with INKT. Release Date: November 14, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript MiNK Therapeutics Inc ( NASDAQ:INKT ) has made significant advancements in their iNKT cell therapy platform, which is poised to be scalable and transformative for treating solid tumor cancers and other immune-related diseases. The company has achieved a 60% reduction in operating burn compared to the previous year, demonstrating improved operational efficiency. MiNK Therapeutics Inc ( NASDAQ:INKT ) has strengthened its leadership
Show less
Read more
Impact Snapshot
Event Time:
INKT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INKT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INKT alerts
High impacting MiNK Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
INKT
News
- MiNK Therapeutics, Inc. (NASDAQ: INKT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.MarketBeat
- MiNK Therapeutics, Inc. (NASDAQ: INKT) had its price target lowered by analysts at Robert W. Baird from $8.00 to $4.00. They now have an "outperform" rating on the stock.MarketBeat
- MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update [Yahoo! Finance]Yahoo! Finance
- MiNK Therapeutics Reports Third Quarter 2024 Results and Business UpdateGlobeNewswire
- MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial ReportGlobeNewswire
INKT
Earnings
- 11/14/24 - Beat
INKT
Sec Filings
- 11/14/24 - Form 10-Q
- 11/14/24 - Form 8-K
- 10/31/24 - Form 8-K
- INKT's page on the SEC website